Altered vascular function in early stages of heart failure in hamsters

M J Crespo1, P I Altieri, N Escobales

  • 1Department of Pharmacology, University of Puerto Rico Medical School, San Juan 00936-5067, USA.

Insights

Young Syrian cardiomyopathic hamsters show enhanced vascular contractility and endothelial dysfunction, suggesting a predisposition to heart failure due to altered vascular function and renin-angiotensin system activity.

Area of Science:

  • Cardiovascular Research
  • Vascular Physiology
  • Heart Failure Pathophysiology

Background:

  • Congestive heart failure involves neurohumoral imbalances affecting the vascular wall.
  • The precise etiology of heart failure remains largely undefined.
  • Syrian cardiomyopathic hamsters (SCHs) offer a model to study pre-clinical heart failure.

Purpose of the Study:

  • To investigate vascular function in young SCHs before the onset of heart failure.
  • To evaluate angiotensin-converting enzyme activity in SCHs.
  • To elucidate the early pathophysiology of heart failure in this model.

Main Methods:

  • Vascular contractility of aortic rings to angiotensin II and norepinephrine.
  • Endothelial function assessed via acetylcholine-induced vasorelaxation.
  • Angiotensin-converting enzyme activity measured in aorta, plasma, and heart tissue.

Main Results:

  • Aortic rings from SCHs showed a 35% greater pressor response to angiotensin II.
  • Angiotensin-converting enzyme activity was threefold higher in SCH aorta homogenates.
  • Endothelial dysfunction was evident in SCHs, with reduced acetylcholine-induced relaxation (53% decrease).

Conclusions:

  • Young SCHs exhibit enhanced vascular contractility, potentially predisposing them to heart failure.
  • This enhanced contractility may stem from increased local renin-angiotensin system activity.
  • Reduced nitric oxide synthesis and enhanced prostaglandin production may also contribute.
Abstract

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
391
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
356
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
993
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
947
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.9K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K